Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Melanoma

Clinical Trials, Melanoma

Pyrexia Management in Patients with Melanoma Treated with Dabrafenib/Trametinib Combination Therapy

Meeting Highlights

NCCN Highlights, Melanoma

New Standards of Care for Melanoma

FDA Oncology Update, Melanoma, Immunotherapy

Opdualag, a Novel Immunotherapy Combination, FDA Approved for Advanced Melanoma

Case Reports, Adverse Events, Melanoma, Checkpoint Inhibitors

Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine

Parikshit Padhi, MD, MBBS, Traci M. White, PharmD, PhC, BCGP, Neslihan Cetin, MD

Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD

Melanoma

Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases

Melanoma

Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease

Melanoma

Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media

Melanoma

Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma

Melanoma

Combination Ipilimumab/Nivolumab Better Than Single-Agent Anti–PD-1 Regardless of BRAF Status in Advanced Melanoma

Melanoma

Meaningful Response Possible with Third-Line Targeted Therapy Rechallenge for Patients with BRAF-Mutation–Positive Advanced Melanoma

Page 1 of 2
Results 1 - 10 of 17